What is an occlusive prostate?
What is an occlusive prostate?
A prostate occlusion doesn’t cause cancer and exists in the glands of the prostate. Prostate occlusions are actually one of the most widely found types of noncancerous cell growth for males. In most cases, the occlusion starts in younger men in the microscopic nodules.
What is the pathogenesis of BPH?
BPH involves the stromal and epithelial elements of the prostate arising in the periurethral and transition zones of the gland (see Pathophysiology). The hyperplasia presumably results in enlargement of the prostate that may restrict the flow of urine from the bladder.
How does BPH cause frequency?
Such a condition is called low-compliance bladder. In this condition, not much urine can be held in the bladder and urinary frequency occurs. It has been reported that benign prostatic enlargement (BPE) causes extension of the urethra and prostatic capsule, and sensory nerves present in the capsule are stimulated.
What does it mean to have benign prostate hypertrophy?
Benign prostate hypertrophy, also called prostate enlargement or BPH, is a non-cancerous enlargement of the prostate gland. The prostate enlarges slowly, and over time puts increasing pressure on the urethra and the base of the bladder.
Are there any side effects of benign prostatic hyperplasia?
The complications of benign prostatic hyperplasia may include Most men with benign prostatic hyperplasia do not develop these complications. However, kidney damage in particular can be a serious health threat when it occurs.
Are there any drugs for benign prostatic hypertrophy?
Drugs for benign prostatic hypertrophy – NPS MedicineWise Alpha1a adrenergic receptor inhibition with selective (tamsulosin, silodosin, terazosin, alfuzosin) or non-selective (prazosin) drugs treat the dynamic component of benign prostatic hyperplasia by relaxing smooth muscle in the prostate and bladder neck
When does benign prostatic hyperplasia occur in men?
Benign prostatic hyperplasia (BPH) is a non-neoplastic glandular and stromal hyperplasia of the transition zone of the prostate.It is a common disorder affecting ∼ 40% of the male population by the age of 50 years.